Women's experiences of having an early medical abortion at home

2016 ◽  
Vol 9 ◽  
pp. 48-54 ◽  
Author(s):  
Maria Hedqvist ◽  
Lina Brolin ◽  
Tanja Tydén ◽  
Margareta Larsson
2020 ◽  
pp. bmjsrh-2020-200661 ◽  
Author(s):  
Jeni Harden ◽  
Julie Ancian ◽  
Sharon Cameron ◽  
Nicola Boydell

BackgroundBetween 2017 and 2019, legislation was introduced in the UK that approved the home as a place for self-administration of misoprostol for early medical abortion. While research has shown that early medical abortion at home is as safe as in a clinical setting, women’s experiences in the UK in the light of this change have not yet been investigated. This qualitative research explored the experiences of women in one region of Scotland, UK who accessed early medical abortion with home self-administration of misoprostol.MethodsQualitative interviews were conducted with 20 women who had recently undergone early medical abortion (≤69 days' gestation) with home self-administration of misoprostol. The data were analysed thematically using an approach informed by the Framework analytic approach.ResultsWomen appreciated the flexibility that home administration of misoprostol offered, including the opportunity to control the timing of the abortion. This was particularly important for women who sought not to disclose the abortion to others. Most women valued being in the comfort and privacy of the home when preparing for self-administration, although a small number highlighted some concerns about being at home. Most women reported that self-administration of misoprostol was straightforward; however, some expressed concerns around assessing whether their experiences were ‘normal’.ConclusionsWomen welcomed the opportunity for home self-administration of misoprostol. To further improve women’s early medical abortion experience we suggest that the legislation be amended so that women can self-administer in an appropriate non-clinical setting, not just their home.


Contraception ◽  
2004 ◽  
Vol 70 (6) ◽  
pp. 487-491 ◽  
Author(s):  
Selma Hajri ◽  
Jennifer Blum ◽  
Nabiha Gueddana ◽  
Habib Saadi ◽  
Leila Maazoun ◽  
...  

2010 ◽  
Vol 5 (4) ◽  
pp. 335-347 ◽  
Author(s):  
B. Ganatra ◽  
S. Kalyanwala ◽  
B. Elul ◽  
K. Coyaji ◽  
S. Tewari

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ciara M. E. Daly ◽  
Lynette Loi ◽  
Jo Booth ◽  
Dalia Saidan ◽  
Karen Guerrero ◽  
...  

Abstract Background Transcutaneous tibial nerve stimulation (TTNS) has been used to treat overactive bladder (OAB), however patient experiences and views of this treatment are lacking. The aim of this study was to explore women’s experiences of OAB and TTNS treatment and the perceived factors influencing participation and adherence. Methods Semi-structured, individual interviews conducted as part of a mixed-methods, randomised, feasibility trial of self-managed versus HCP-led TTNS. Interviews were audio recorded and transcribed verbatim. Reflexive thematic analysis was undertaken using Booth et al. (Neurourol Urodynam. 2017;37:528–41) approach. Results 16 women were interviewed, 8 self-managing TTNS at home and 8 receiving TTNS in twice-weekly hospital clinic appointments. Women self-managing OAB considered TTNS easy to administer, flexible and favourably ‘convenient’, especially when the participant was bound by work and other life commitments. In contrast to OAB symptoms ‘dominating life’, self-managing bladder treatment was empowering and fitted around home life demands. Flexibility and control engendered by self-management, facilitated women’s willingness to participate in TTNS. Women attending a hospital clinic for TTNS enjoyed the social aspects but found the routine appointments constrained their lives. Motivation to continue TTNS in the longer term was dependent on perception of benefit. Conclusions This study provides novel insights into women’s experiences of self-managing their OAB using TTNS compared to HCP-led management in the clinical setting. It highlights positive experiences self-managing TTNS at home and a willingness to continue in the longer term, facilitated by ease of use and convenience. Trial Registration 1/11/2018: ClinicalTrials.gov Identifier: NCT03727711.


Sign in / Sign up

Export Citation Format

Share Document